Search company, investor...
Lucina Health company logo

Lucina Health

Submit Your Analyst Briefing

lucinahealth.com

Executives

8

Board of Directors

3

Lucina Health Management Team

8 Team Members

Lucina Health has 8 executives. Lucina Health's founder is Michael Ross. Lucina Health's is .

Name

Work History

Title

Status

Michael Ross

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael Ross

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

This profile has not been claimed.

Highlight your management team’s expertise.

Lucina Health Board of Directors

3 Board of directors

Lucina Health has 3 board of directors, including George Dunbar.

Name

Firm

Work History

Other Seats

George Dunbar

Mr. Dunbar has extensive healthcare and life sciences operating experience, and has served as a Director or CEO with private and public companies in Diagnostics, Specialty Pharma, Cell Therapy, and Biologics, two where he led initial public offerings (IPOs). George has served as a Director or CEO with life science companies including Stem Cells, Inc./ CytoTherapeutics, Aastrom (now Vericel) and also DepoTech, Epic Therapeutics, LJL Biosystems, Metra Biosystems, Metrika, Molecular Probes, Quantum Dot, Sonus Pharmaceuticals, and Quidel. He began his career with Motorola’s Communications Division. Mr. Dunbar has degrees in Electrical Engineering and an MBA from Auburn University, and served on the Harbert College of Business MBA Advisory Board. He is member of the Entrepreneurial Advisory Council with Vanderbilt University’s Center for Technology Transfer and Commercialization.

Lucina Health

Koleman Karleski

Koleman joined Chrysalis in 1997 and is currently a Managing Director. His focus is on investment opportunities in healthcare. At Chrysalis, Koleman has worked with HealthMedia (sold to Johnson & Johnson), Aperture Credentialing (sold to a subsidiary of UnitedHealth Group), Manorhouse Assisted Living (sold to LifeTrust Assisted Living), Primis (sold to LandAmerica Financial Group), and TechRepublic (sold to Gartner Group, Inc.). He currently serves on the Board of AfterBOT, Cervilenz, Chronicity, Foundation Radiology Group, HealthTeacher, MedServe, and NextImage Medical. He also spearheads Chrysalis fundraising efforts. Prior to Chrysalis, Koleman worked for Providian Corporation&#8217

Lucina Health

Thomas Shehab

Over 25 years of diverse healthcare experience as a physician, healthcare executive, and successful venture capitalist

Lucina Health

Name

George Dunbar

Koleman Karleski

Thomas Shehab

Firm

Work History

Mr. Dunbar has extensive healthcare and life sciences operating experience, and has served as a Director or CEO with private and public companies in Diagnostics, Specialty Pharma, Cell Therapy, and Biologics, two where he led initial public offerings (IPOs). George has served as a Director or CEO with life science companies including Stem Cells, Inc./ CytoTherapeutics, Aastrom (now Vericel) and also DepoTech, Epic Therapeutics, LJL Biosystems, Metra Biosystems, Metrika, Molecular Probes, Quantum Dot, Sonus Pharmaceuticals, and Quidel. He began his career with Motorola’s Communications Division. Mr. Dunbar has degrees in Electrical Engineering and an MBA from Auburn University, and served on the Harbert College of Business MBA Advisory Board. He is member of the Entrepreneurial Advisory Council with Vanderbilt University’s Center for Technology Transfer and Commercialization.

Koleman joined Chrysalis in 1997 and is currently a Managing Director. His focus is on investment opportunities in healthcare. At Chrysalis, Koleman has worked with HealthMedia (sold to Johnson & Johnson), Aperture Credentialing (sold to a subsidiary of UnitedHealth Group), Manorhouse Assisted Living (sold to LifeTrust Assisted Living), Primis (sold to LandAmerica Financial Group), and TechRepublic (sold to Gartner Group, Inc.). He currently serves on the Board of AfterBOT, Cervilenz, Chronicity, Foundation Radiology Group, HealthTeacher, MedServe, and NextImage Medical. He also spearheads Chrysalis fundraising efforts. Prior to Chrysalis, Koleman worked for Providian Corporation&#8217

Over 25 years of diverse healthcare experience as a physician, healthcare executive, and successful venture capitalist

Other Seats

Lucina Health

Lucina Health

Lucina Health

You May Also Like

Moximed Logo
Moximed

Moximed is a developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA). The Moximed implants do not require bone cutting or bone removal, and, importantly, they absorb excess joint load rather than shift load to other areas of the joint. The company is based in Fremont, California.

P
Precision Parts International

PPI was formed from the merger of three companies (MPI International, Skill Tool & Die, and Precision Gear) to manufacture complex, high-precision metal components for the automotive, defense, medical device and construction industries.

C
Cerene Biomedics

Cerene Biomedics is developing an implantable medical device that will prevent epileptic seizures

O
Otothera Corporation

Otothera Corporation is a medical device company developing products to diagnose and treat the more than seven million severe tinnitus (constant ringing in the ears) sufferers in the US. The company was originally named AudioFusion. The company was a 2006 PTEN Growth Accelerator (GAP) winner.

s
synecor

synecor is a medical device developer

Tears for Life Logo
Tears for Life

Tears For Life, a medical diagnostic equipment company currently developing a non-invasive tear test kit that will be able to screen women for breast cancer using proteins found in their tears.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.